Algoma Central (TSE:ALC) Stock Crosses Above Fifty Day Moving Average – Should You Sell?

Swiss stocks ended higher on Thursday after a cautious start. The SMI rose 0.93% to close at 13,341.27 (intraday high 13,395.00). Roche gained 4.2% after developing a research-use-only PCR test for the rare Ebola Bundibugyo virus. Partners Group rose 3.73%; Novartis, Alcon, Sonova and SGS gained 1.6%-2%. Switzerland’s unemployment rate held at 3% in May, SECO said.

Swiss shares ended flat on Tuesday as gains faded while investors weighed differing accounts of Middle East talks between U.S. President Donald Trump and Israeli PM Benjamin Netanyahu. The SMI finished at 13,305.72 versus 13,305.40. VAT Group (+5%), Logitech (+3.7%) and ABB (+3.21%) rose; Roche and Swiss Re fell 1.4%-2.5%. Switzerland’s trade surplus widened to CHF 3.2bn in April.

Swiss stocks fell on Thursday as investors stayed cautious amid Middle East tension worries. The SMI ended down 122.65 points (0.9%) at 13,504.76 after opening weak and trading in negative territory. Losers included Partners Group, Swiss Life, Julius Baer, Zurich and Sonova (-2% to -2.5%). Kuehne+Nagel and Lonza rose (+1% to +1.5%). Switzerland non-farm payrolls rose 0.5% y/y to 5.537 million in Q1 2026, per the Federal Statistical Office.

FNArena launched “The Australian Broker Call Extra Edition,” which adds additional broker research coverage but is updated “regularly” rather than daily, so post-publication information may lag. The issue summarizes broker views on ASX stocks including AFT Pharmaceuticals (Jarden Overweight; target NZ$4.25) and Alligator Energy (Argonaut Speculative Buy; $0.07 target), plus Alcidion Group (Canaccord Buy; $0.14 target) and Moelis Buy ($0.16).

Alcon Inc. (CH0432492467) offers investors defensive exposure to the eye care sector through its global leadership in surgical devices, contact lenses, and pharmaceuticals. The company's dual business model, focusing on both Surgical and Vision Care, along with significant R&D investment, provides stable cash flows and pricing power. This positions Alcon for steady growth driven by an aging global population and rising vision needs, making it a resilient option for long-term portfolios despite potential risks like reimbursement cuts and supply chain disruptions.

Systane eye drops, produced by Alcon, offer fast and long-lasting relief for dry and irritated eyes, a common issue in North America exacerbated by screen time and environmental factors. The product utilizes a unique gel-forming technology for extended hydration and is a significant part of Alcon's consumer health portfolio. Its strong market position and brand loyalty contribute to Alcon's stable revenue and shareholder value, appealing to investors in the resilient eye care sector.